Literature DB >> 11748176

CpG oligodeoxynucleotides enhance host defense during murine tuberculosis.

Nicole P Juffermans1, Jaklien C Leemans, Sandrine Florquin, Annelies Verbon, Arend H Kolk, Peter Speelman, Sander J H van Deventer, Tom van der Poll.   

Abstract

Oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs activate immune cells to produce cytokines. CpG ODNs protect mice against infections with intracellular bacteria by the induction of a T helper 1 (Th1) response. To determine the effect of CpG ODNs in pulmonary tuberculosis, mice were treated with CpG ODNs or control ODNs at the time of intranasal infection. CpG ODNs reduced mycobacterial outgrowth for up to 5 weeks after Mycobacterium tuberculosis infection and were associated with a decrease in inflammation in lung tissue. CpG treatment was also associated with elevated levels of gamma interferon (IFN-gamma) and decreased levels of interleukin 4 in the lungs and an increased capacity of splenocytes to secrete Th1-type cytokines. CpG ODNs given 2 weeks after infection were still able to reduce mycobacterial outgrowth and to enhance a Th1 response 5 weeks postinfection. Administration of CpG ODNs to IFN-gamma-gene-deficient mice failed to reduce mycobacterial outgrowth. These data suggest that CpG ODNs improve host defense during pulmonary tuberculosis by an IFN-gamma-dependent mechanism.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11748176      PMCID: PMC127605          DOI: 10.1128/IAI.70.1.147-152.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  The role of CpG motifs in innate immunity.

Authors:  A M Krieg
Journal:  Curr Opin Immunol       Date:  2000-02       Impact factor: 7.486

2.  Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection.

Authors:  D M Klinman; J Conover; C Coban
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

3.  Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides.

Authors:  S Sur; J S Wild; B K Choudhury; N Sur; R Alam; D M Klinman
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

4.  Immunostimulatory bacterial DNA sequences activate dendritic cells and promote priming and differentiation of CD8+ T cells.

Authors:  R E Tascon; S Ragno; D B Lowrie; M J Colston
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

5.  CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.

Authors:  M J McCluskie; H L Davis
Journal:  J Immunol       Date:  1998-11-01       Impact factor: 5.422

6.  Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria.

Authors:  K L Elkins; T R Rhinehart-Jones; S Stibitz; J S Conover; D M Klinman
Journal:  J Immunol       Date:  1999-02-15       Impact factor: 5.422

7.  Interleukin-1 signaling is essential for host defense during murine pulmonary tuberculosis.

Authors:  N P Juffermans; S Florquin; L Camoglio; A Verbon; A H Kolk; P Speelman; S J van Deventer; T van Der Poll
Journal:  J Infect Dis       Date:  2000-08-17       Impact factor: 5.226

8.  CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms.

Authors:  D Askew; R S Chu; A M Krieg; C V Harding
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

9.  CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis.

Authors:  B L Freidag; G B Melton; F Collins; D M Klinman; A Cheever; L Stobie; W Suen; R A Seder
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

10.  Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project.

Authors:  C Dye; S Scheele; P Dolin; V Pathania; M C Raviglione
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

View more
  31 in total

1.  Contribution of nitric oxide to CpG-mediated protection against Listeria monocytogenes.

Authors:  Shuichi Ito; Ken J Ishii; Atsushi Ihata; Dennis M Klinman
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

Review 2.  The impact of successive infections on the lung microenvironment.

Authors:  Arnaud Didierlaurent; John Goulding; Tracy Hussell
Journal:  Immunology       Date:  2007-12       Impact factor: 7.397

3.  A novel gonorrhea vaccine composed of MetQ lipoprotein formulated with CpG shortens experimental murine infection.

Authors:  Aleksandra E Sikora; Carolina Gomez; Adriana Le Van; Benjamin I Baarda; Stephen Darnell; Fabian G Martinez; Ryszard A Zielke; Josephine A Bonventre; Ann E Jerse
Journal:  Vaccine       Date:  2020-11-05       Impact factor: 3.641

4.  Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs.

Authors:  Barbara Flynn; Vivian Wang; David L Sacks; Robert A Seder; Daniela Verthelyi
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

5.  The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques.

Authors:  Yichuan Wang; Kristina Abel; Katherine Lantz; Arthur M Krieg; Michael B McChesney; Christopher J Miller
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

6.  Tweaking Innate Immunity: the Promise of Innate Immunologicals As Anti-infectives.

Authors:  Kenneth L Rosenthal
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-09       Impact factor: 2.471

7.  Limited effect of CpG ODN in preventing type 1 diabetes in NOD mice.

Authors:  Byong Jun Lee; Soo Kie Kim; Moon Kyu Kim; Eon Sub Park; Hyun Chul Cho; Myung Sook Shim; Mi Jin Kim; Young Goo Shin; Choon Hee Chung
Journal:  Yonsei Med J       Date:  2005-06-30       Impact factor: 2.759

8.  Pulmonary mucosal immunity mediated through CpG provides adequate protection against pulmonary Mycobacterium tuberculosis infection in the mouse model. A role for type I interferon.

Authors:  Amber Troy; Sandra C Esparza-Gonzalez; Alicia Bartek; Elizabeth Creissen; Linda Izzo; Angelo A Izzo
Journal:  Tuberculosis (Edinb)       Date:  2020-06-06       Impact factor: 3.131

9.  Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2.

Authors:  Ali A Ashkar; Stefan Bauer; William J Mitchell; Jeff Vieira; Kenneth L Rosenthal
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

10.  Intratracheal synthetic CpG oligodeoxynucleotide causes acute lung injury with systemic inflammatory response.

Authors:  Sadatomo Tasaka; Hirofumi Kamata; Keisuke Miyamoto; Yasushi Nakano; Hiromi Shinoda; Yoshifumi Kimizuka; Hiroshi Fujiwara; Naoki Hasegawa; Seitaro Fujishima; Taku Miyasho; Akitoshi Ishizaka
Journal:  Respir Res       Date:  2009-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.